10-Q: Ginkgo Bioworks Narrows Losses Amid Restructuring

Ginkgo Bioworks Holdings, Inc. reported a significant reduction in net and operating losses for Q2 and H1 2025, driven by ongoing restructuring efforts and expense reductions, despite a decline in Biosecurity revenue.

Summary

• Total revenue for the three months ended June 30, 2025, was $49.6 million, a decrease of $6.6 million from $56.2 million in the same period of 2024.
• Total revenue for the six months ended June 30, 2025, was $97.9 million, an increase of $3.8 million from $94.2 million in the same period of 2024.
• Cell Engineering revenue increased by $2.9 million to $39.1 million for Q2 2025 and by $13.3 million to $77.4 million for H1 2025, primarily due to programs with large enterprise customers in pharmaceutical, biotechnology, and U.S. government sectors.
• Biosecurity revenue decreased by $9.5 million to $10.5 million for Q2 2025 and to $20.6 million for H1 2025, mainly due to lower revenue from a U.S. government program.
• Net loss significantly improved to $(60.3) million for Q2 2025 from $(217.2) million for Q2 2024, and to $(151.3) million for H1 2025 from $(383.1) million for H1 2024.
• Loss from operations improved to $(65.5) million for Q2 2025 from $(222.9) million for Q2 2024, and to $(154.5) million for H1 2025 from $(400.9) million for H1 2024.
• Research and development expenses decreased by $80.9 million to $53.4 million for Q2 2025 and by $146.4 million to $124.3 million for H1 2025, largely due to the ongoing restructuring plan.
• General and administrative expenses decreased by $23.0 million to $43.3 million for Q2 2025 and by $44.3 million to $92.3 million for H1 2025, also driven by restructuring.
• No goodwill impairment was recorded in 2025, compared to a $47.9 million charge in 2024.
• Restructuring charges were $3.7 million for Q2 2025 and $8.9 million for H1 2025, down from $17.1 million for both periods in 2024.
• Cash and cash equivalents were $203.6 million as of June 30, 2025, down from $561.6 million as of December 31, 2024.
• Net cash used in operating activities improved to $(91.8) million for H1 2025 from $(173.6) million for H1 2024.
• The company began investing excess cash in marketable debt securities in 2025, holding $270.1 million as of June 30, 2025.
• The company expects to incur a contractual liability of approximately $24.0 million related to a minimum purchase obligation with Google Cloud by August 27, 2025.
• An amendment to the Twist supply agreement converted remaining minimum annual commitments into non-refundable payments of $5.0 million due April 1, 2026, and $6.0 million due April 1, 2027.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvement in reducing its net and operating losses, driven by substantial expense reductions from its restructuring efforts. While Biosecurity revenue declined, Cell Engineering revenue showed growth. The cash position, though decreased, is deemed sufficient for the next 12 months. The overall sentiment is positive due to the strong progress in cost control and loss reduction, despite some revenue headwinds.

Positives

• Net loss significantly reduced by $156.9 million in Q2 2025 and $231.8 million in H1 2025 compared to the prior year periods.
• Operating loss substantially decreased by $157.4 million in Q2 2025 and $246.4 million in H1 2025, reflecting effective cost control.
• Research and development expenses decreased by over 50% in both Q2 and H1 2025, indicating successful rationalization of development programs.
• General and administrative expenses saw a significant reduction of over 30% in both Q2 and H1 2025 due to restructuring efforts.
• No goodwill impairment charge was recorded in 2025, compared to a $47.9 million charge in 2024.
• Net cash used in operating activities improved by $81.9 million in H1 2025, demonstrating better operational cash management.
• Cell Engineering revenue increased, driven by new programs with large enterprise customers in key industries like pharmaceutical, biotechnology, and government.

Negatives

• Total revenue decreased by $6.6 million in Q2 2025 compared to Q2 2024.
• Biosecurity revenue significantly declined by $9.5 million in both Q2 and H1 2025, primarily due to lower revenue from a U.S. government program.
• Cash and cash equivalents decreased substantially from $561.6 million at December 31, 2024, to $203.6 million at June 30, 2025.
• The company anticipates a potential $24.0 million contractual liability for a shortfall in minimum spend with Google Cloud by August 27, 2025.
• Non-cash Cell Engineering revenue from prior contracts decreased from $8.2 million in Q2 2024 to $1.2 million in Q2 2025, and from $12.1 million in H1 2024 to $9.9 million in H1 2025.
• The company continues to operate at a net loss, despite significant improvements.

Risks

• Intense competition and competitive pressures from other companies worldwide in the industries in which the company operates.
• Litigation, including securities or shareholder litigation, and the ability to adequately protect intellectual property rights.
• Rapidly changing technology and extensive competition in the synthetic biology industry that could make products and processes obsolete or non-competitive.
• Reliance on customers to develop, produce, and manufacture products using engineered cells and/or biomanufacturing processes.
• Ability to accurately predict customer demand, including with respect to data access and holding.
• Ability to comply with laws and regulations applicable to the business.
• Market conditions and global and economic factors beyond the company's control, including U.S. government initiatives in biotechnology.
• The frequency and scale of biological risks and threats.
• The future potential and commercial applications of artificial intelligence (AI) and the biotechnology sector.
• Exposure to volatility and liquidity risks inherent in holding equity or convertible debt interests in certain customers.
• Ability to raise additional capital in the future.
• Ability to effectively manage organizational changes, including restructuring actions and facility consolidations, and related impacts on financial performance.
• Costs required to maintain, expand, and protect intellectual property.

Future Outlook

Research and development (R&D) and general and administrative (G&A) expenses are expected to remain consistent or decline in 2025 compared to 2024, reflecting the stabilization of operational overhead and the impact of restructuring actions. However, these expenses could increase due to employee incentive programs or additional costs arising from restructuring. The company intends to maintain a strategic and opportunistic approach regarding inorganic G&A expenses from mergers, acquisitions, and other inorganic growth initiatives.

Management Comments

• Our R&D expenses were lower in the first half of 2025 compared to the first half of 2024, primarily due to our restructuring plan announced and commenced in the second quarter of 2024 as we rationalize our current development programs and prioritize our investments in our Foundry, Codebase and cell engineering tools offerings.
• We expect that our R&D expenses will either remain consistent or decline in 2025 as compared to 2024, reflecting the stabilization of our operational overhead and the impact of our restructuring actions.
• Our G&A expenses were lower in the first half of 2025 compared to the first half of 2024, primarily due to our restructuring plan announced and commenced in the second quarter of 2024, as we began reducing our operational overhead.
• We expect that our G&A expenses will either remain consistent or decline in 2025 as compared to 2024, reflecting the stabilization of our operational overhead and the impact of our restructuring actions.
• We intend to maintain a strategic and opportunistic approach regarding inorganic G&A expenses arising from mergers, acquisitions, and other inorganic growth initiatives.
• We believe our cash and cash equivalents and marketable securities of $473.7 million as of June 30, 2025, will be sufficient to enable us to fund our projected operations through at least the next 12 months from the date of filing.

Industry Context

Ginkgo Bioworks operates in the synthetic biology industry, aiming to make biology easier to engineer. The company provides biological research and development (R&D) services across multiple markets, leveraging its Foundry (equipment, automation, software, data) and Codebase (biological assets, performance data). It also has a Biosecurity business focused on biomonitoring and bioinformatics to identify, monitor, prevent, and mitigate biological threats, primarily for governments. The company's strategy involves expanding its Cell Engineering offerings to include tools like Datapoints and lab automation solutions, alongside its traditional end-to-end solutions. The industry is characterized by rapidly changing technology and intense competition, with a growing focus on AI and biotechnology applications.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for benchmarking against global industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be named as a defendant in lawsuits, indemnity claims, and other legal proceedings in the ordinary course of business.
• No pending litigation is believed to be material, nor is the outcome of any such litigation expected to have a material adverse effect on the company's results of operations, cash flows, or financial condition.

Related Party Transactions

• Cell Engineering revenue from related parties was $0.42 million for Q2 2025 (down from $5.146 million in Q2 2024) and $8.518 million for H1 2025 (up from $5.819 million in H1 2024).
• In February 2025, the company and Motif FoodWorks, Inc. mutually agreed to terminate Motif's sublease, with Motif paying a $1.6 million termination fee.
• In March 2025, the company and BiomEdit, Inc. mutually terminated certain agreements, resulting in the recognition of $7.5 million in previously deferred non-cash revenue related to material rights.

Stakeholder Impact

• Shareholders: Benefit from significantly reduced net and operating losses, indicating improved financial health. However, the decrease in cash and cash equivalents and potential future capital raises could lead to dilution.
• Employees: Impacted by ongoing workforce reductions as part of the restructuring plan, but also benefit from new employee incentive programs.
• Customers: Cell Engineering customers benefit from expanded service offerings (Datapoints, lab automation solutions) and revised commercial terms more favorable to them. Biosecurity customers may experience changes due to reduced revenue from a U.S. government program.
• Suppliers: The company's amended agreement with Twist involves non-refundable payments, ensuring continued business for the supplier, but the potential Google Cloud shortfall could impact that relationship.
• Creditors: The company's improved operating cash flow and stated liquidity for the next 12 months suggest a stable financial position for meeting short-term obligations.

Next Steps

• Substantially complete workforce reductions in 2025.
• Continue facility consolidation actions, with efforts to sublease unused or underutilized facilities.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Manage potential $24.0 million shortfall liability for Google Cloud minimum spend by August 27, 2025.
• Make obligated non-refundable payments to Twist of $5.0 million on April 1, 2026, and $6.0 million on April 1, 2027.

Key Dates

Recommendation

While Ginkgo Bioworks has made significant strides in reducing its net and operating losses through aggressive cost control and restructuring, the decline in Biosecurity revenue and the substantial decrease in cash and cash equivalents warrant caution. The company's ability to fund operations for the next 12 months is positive, but the long-term path to profitability and sustained revenue growth, especially in the Biosecurity segment, remains uncertain. The ongoing restructuring and potential liabilities like the Google Cloud shortfall introduce execution risks. For a seasoned investor, the improved financial efficiency is a positive signal, but the mixed revenue performance and continued cash burn suggest a 'hold' position until clearer trends in revenue growth and sustained profitability emerge.

Keywords

Synthetic Biology, Cell Engineering, Biosecurity, Biotechnology, Genomics, AI, R&D, SEC Filing, Financial Results, Restructuring, Ginkgo Bioworks, 10-Q